Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DuoGenic StemCellsROCO:7607 -0.76%25 Days Inventory is 216.13 as of Dec. 2025, which is 36% below its 10-year median of 336.11. GuruFocus rates ROCO:7607 with a GF Score™ of 25/100 and a GF Value™ of NT$51.22 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, DuoGenic StemCells ranks worse than 64.42% on this metric.
The historical rank and industry rank for DuoGenic StemCells's Days Inventory or its related term are showing as below:
ROCO:7607'
s Days Inventory Range Over the Past 10 Years
Min: 177.57 Med: 336.11 Max: 372.62
Current: 265.59
During the past 5 years, DuoGenic StemCells's highest Days Inventory was 372.62. The lowest was 177.57. And the median was 336.11.
ROCO:7607's Days Inventory is ranked worse than 64.42% of 638
companies
in the Biotechnology industry
Industry Median: 183.195
vs ROCO:7607: 265.59
DuoGenic StemCells's Days Inventory
declined
from Dec. 2024 (218.22) to Dec. 2025 (216.13).
Inventory Turnover measures how fast the company turns over its inventory within a year.
DuoGenic StemCells's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.84.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
DuoGenic StemCells's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.31.
DuoGenic StemCells (ROCO:7607) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
DuoGenic StemCells's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
DuoGenic StemCells's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
DuoGenic StemCells Days Inventory Related Terms
DuoGenic StemCells Days Inventory Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, DuoGenic StemCells's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Days Inventory distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DuoGenic StemCells (ROCO:7607) has a Days Inventory of 216.13 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on DuoGenic StemCells and its competitors. This is 36% below median its historical median of 336.11. Over the past decade, DuoGenic StemCells' Days Inventory has ranged from 177.57 to 372.62. According to the industry distribution chart, DuoGenic StemCells ranks #411 out of 638 companies in the Biotechnology industry, placing it in the top 64.4%.
Is DuoGenic StemCells' Days Inventory too high?
DuoGenic StemCells' current Days Inventory of 216.13 is 36% below median its 10-year median of 336.11. Over the past 10 years, this metric has ranged from a low of 177.57 to a high of 372.62. The Biotechnology industry median Days Inventory is 183.20. DuoGenic StemCells' value of 216.13 is 18% above this industry median. Based on the distribution chart, DuoGenic StemCells ranks #411 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #411 out of 638 companies for Days Inventory. This places DuoGenic StemCells in the lower half of its industry. The industry median Days Inventory is 183.20. DuoGenic StemCells' value of 216.13 is 18% above this benchmark. Historically, DuoGenic StemCells' own Days Inventory has ranged from 177.57 to 372.62 over the past decade. While the company's 10-year median is 336.11 vs. the industry median of 183.20, DuoGenic StemCells has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DuoGenic StemCells's current Days Inventory of 216.13 is 18% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on DuoGenic StemCells and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DuoGenic StemCells's current Days Inventory is 216.13, which is 36% below median its own 10-year median of 336.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.22, compared to a current price of NT$13.00 — trading 74.6% below its estimated fair value. The current Days Inventory is 216.13, which is 36% below median its 10-year median of 336.11 and 18% above the Biotechnology industry median of 183.20. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Days Inventory is 216.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$13.00 is trading 74.6% below its estimated GF Value™ of NT$51.22.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Days Inventory: 216.13 (36% below median its 10-year median of 336.11)
GF Value™: NT$51.22 vs. price of NT$13.00 (74.6% below fair value)
Industry Position: 18% above the Biotechnology median (#411 of 638)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score
Get the complete analysis for ROCO:7607
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
